Micromet announced the commencement of a randomized, controlled phase 2 trial of its human anti-EpCAM IgG1 antibody adecatumumab (MT201) for the treatment of patients with colorectal cancer (CRC) after complete resection of liver metastases. The trial has three arms comparing single agent adecatumumab to combination chemotherapy (FOLFOX: 5-FU/leucovorin plus oxaliplatin), and to FOLFOX followed by adecatumumab. The primary endpoint will be the disease-free survival rate at one year.

For more information please call (240) 752-1420 or visit www.micromet-inc.com.